Warburton returns to captain Lions

Tags: , , , , , , , , , , ,

Warburton returns to captain Lions

first_imgWarren Galtand’s tourists face the Super Rugby franchise in Dunedin on the back of tackling the competition’s dominant force, Crusaders, and beating them 12-3 on Saturday.Returning captain Warburton has not played the last two fixtures due to an ankle injury, while Biggar sat out the Crusaders win due to concussion.The skipper is joined by James Haskell and CJ Stander in the back row, while Iain Henderson replaces Maro Itoje at lock from the Lions’ last midweek match – a 22-16 defeat to Blues – to partner Courtney Lawes.TEAM ANNOUNCEMENT | @samwarburton_ returns to lead the Lions against @Highlanders#HIGvBIL info ️https://t.co/cxdkqLbkhj #LionsNZ2017pic.twitter.com/VU7ckFDw6a— British&Irish Lions (@lionsofficial) 11 June 2017Rhys Webb returns at scrum-half, while Ireland’s Jared Payne will start at full-back, with Robbie Henshaw and Jonathan Joseph in the centres. Jack Nowell is given another go on the wing despite struggling against the Blues, with Tommy Seymour lining up on the left.The front three of Joe Marler, Rory Best and Kyle Sinckler that started the first game of the tour will do so again on Tuesday.Gatland said: “At this stage of the tour everyone has had a start and as coaches we are happy that all the players have had a chance to put their hand up and perform in the Lions jersey.”Each game is a chance for individuals to shine but more importantly it’s about a collective performance. We are building some momentum and we have improved with every game.”We were obviously pleased with the win against the Crusaders, especially our defence and game management, but we know the Highlanders will be another massive test for us as a squad.”Highlanders will be missing All Blacks Ben Smith and Aaron Smith for the clash, but New Zealand international trio Malakai Fekitoa, Waisake Naholo and Lima Sopoaga will get a look at the Lions.Here’s #YOURLanders to take on the @lionsofficial on Tuesday! #HighlandersANDyou pic.twitter.com/evRc2lXxZY— The Highlanders (@Highlanders) June 11, 2017British and Irish Lions: Jared Payne, Jack Nowell,  Jonathan Joseph, Robbie Henshaw, Tommy Seymour, Dan Biggar, Rhys Webb; Joe Marler, Rory Best, Kyle Sinckler, Courtney Lawes, Iain Henderson, James Haskell, Sam Warburton, CJ Stander.Replacements: Ken Owens, Jack McGrath, Dan Cole, Alun Wyn Jones, Justin Tipuric, Greig Laidlaw, Owen Farrell, Elliot Daly.Highlanders: Richard Buckman, Waisake Naholo, Malakai Fekitoa, Teihorangi Walden, Tevita Li, Lima Sopoaga, Kayne Hammington; Daniel Lienert-Brown, Liam Coltman, Siate Tokolahi, Alex Ainley, Jackson Hemopo, Gareth Evans, Dillon Hunt, Luke Whitelock.Replacements: Greg Pleasants-Tate, Aki Seiuli, Siosuia Halanukonuka, Josh Dickson, Jimmy Lentjes, Josh Renton, Marty Banks, Patrick Osborne.last_img read more

Continue Reading

Hesperos receives SBIR grant to create humanonachip model to mimic Alzheimers disease

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Aug 29 2018Hesperos, Inc., announced today the receipt of a NIH Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Institute on Aging (NIA) to help create a new multi-organ “human-on-a-chip” model that can realistically mimic the biology of Alzheimer’s Disease (AD) and the effects of potential new therapies under realistic human physiological conditions.Hesperos founders Michael L. Shuler, Ph.D, and James J. Hickman, Ph.D., are pioneers of organ-on-a-chip technology, and their company is the first to create pumpless microfluidic multi-organ systems with fully integrated physiological functions, such as blood circulation and nerve connections.The AD model will be a three-organ system that includes brain cells (cortical neurons) and functioning liver and blood-brain-barrier constructs, as well as re-circulating blood and cerebral spinal fluid surrogates. This will enable scientists to study the body’s systemic response to any chemical introduced into the model, including how it metabolizes in the liver, and how it penetrates into the brain through the blood-brain barrier.This is important, because the toxicity of drugs can change once metabolized. In some cases, they become less effective; in others, the metabolites that are produced can cause unexpected — and sometimes dangerous — effects. Current human-based in vitro toxicity studies have only limited capacity to predict such functional changes, and that has been the demise of many potential therapeutics.”There are estimated to be 50 million people in the world with dementia — that’s more than the population of Spain, and it is projected to nearly triple by 2050. Many of the people with dementia have AD, resulting in an urgent need for new, effective treatment options for the disease,” said Hickman, Hesperos’s chief scientist and professor at the University of Central Florida’s Hybrid Systems Laboratory. “Development of a low-cost, easy-to-use system to assess drugs for AD would improve efficacy and toxicological evaluations for patient specific treatments, providing a significant benefit to the drug development community and patients.”Related StoriesComputers, games, crafting keep the aging brain sharpAI-enabled device detects if targeted chemotherapy is workingScientists discover how resistance to the chemotherapy drug 5-fluorouracil arisesHesperos scientists will make models using both healthy brain cells created from pluripotent stem cells, and cells with different mutations consistent with AD. Functional readouts of responses to drugs administered to the models will give valuable insights into both direct central nervous system effects and peripheral effects.Later phases of the project will also test long-term effects, and include real patient samples, to test its viability as a tool to inform real-time, personalized treatment decisions as part of precision medicine.”The integrated use of these pre-clinical test systems and physiologically based pharmacokinetic/pharmacodynamic models provides a powerful tool for evaluating the dynamic interaction between drugs, aging biological system and disease, and will facilitate rational drug development and clinical trial design,” said Dr. Shuler, Hesperos CEO and founding Chair of the Department of Biomedical Engineering at Cornell University. Source:http://www.hesperosinc.com/last_img read more

Continue Reading